Premium
Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck
Author(s) -
Mirabile Aurora,
Miceli Rosalba,
Calderone Rosa Gioia,
Locati Laura,
Bossi Paolo,
Bergamini Cristiana,
Granata Roberta,
Perrone Federica,
Mariani Luigi,
Licitra Lisa
Publication year - 2019
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25636
Subject(s) - medicine , oncology , proportional hazards model , radiation therapy , head and neck , population , head and neck cancer , head and neck squamous cell carcinoma , progression free survival , confidence interval , survival analysis , overall survival , surgery , environmental health
Background In clinical trials of recurrent and metastatic head and neck carcinoma, Argiris et al have identified prognostic factors for overall survival (OS) and progression‐free survival (PFS), weight loss, Eastern Cooperative Oncology Group performance status (ECOG‐PS), tumor primary site, tumor differentiation, prior radiotherapy, deriving a two‐group prognostic classification. This study evaluates Argiris's classification in “field‐practice” patients. Methods The main analysis included 327 cases; a secondary analysis excluded 31 patients with oropharyngeal carcinoma (OPC) p16‐positive and/or human papilloma virus (HPV)‐positive. OS and PFS curves were estimated with the Kaplan‐Meier method; multivariable Cox analyses were also performed. Results In the full series, OS was significantly different in patients with 0‐2 and ≥3 adverse features (median, 14 vs 10 months; P = .03). PFS was statistically different in the two groups (median, 7 vs 5 months; P = .02). At a multivariable analysis investigating additional prognostic features, site of relapse and disease‐free interval were significant predictors of OS and PFS. Conclusion The Argiris's model was confirmed in a “field‐practice” population. Moreover, we found additional putative prognostic factors.